UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): | August 28, 2015 |
CannaPharmaRx, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
Delaware | 000-27055 | 27-4635140 |
_____________________ (State or other jurisdiction |
_____________ (Commission |
______________ (I.R.S. Employer |
of incorporation) | File Number) | Identification No.) |
One Collins Drive, Suite 100, Carneys Point, New Jersey | 08069 | |
_________________________________ (Address of principal executive offices) |
___________ (Zip Code) |
Registrants telephone number, including area code: | 856-376-0500 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07.
|
Submission of Matters to a Vote of Security Holders. |
On August 28, 2015, CannaPharmaRx, Inc., a Delaware corporation (the Company), held its 2015 Annual Meeting of Stockholders via telephonic conference call and at the Companys headquarters at One Collins Drive, Suite 100, Carneys Point, New Jersey 08069-3640 (the Annual Meeting). At the Annual Meeting, at which a quorum was present, the stockholders of the Company voted on and approved the following matters, which are described in detail in the Companys Definitive Proxy Statement filed with the Securities and Exchange Commission on July 17, 2015:
(1) to elect seven directors;
(2) to conduct an advisory vote on executive compensation;
(3) to conduct an advisory vote on the frequency of future votes on executive compensation;
(4) to ratify the appointment of KLJ & Associates, LLP as the Companys independent public accountants for the year ending December 31, 2015; and
(5) to transact any other business that may properly come before the meeting.
Only stockholders of record as of the close of business on July 10, 2015 were entitled to vote at the Annual Meeting. As of July 10, 2015, 17,959,621 shares of common stock of the Company (Common Shares) were outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 9,014,561 Common Shares were represented, in person or by proxy, constituting a quorum.
The votes with the proposals are set forth below.
(1) Elect the Directors of the Company to serve until the 2016 Annual Meeting:
The following nominees were elected as directors to serve until the 2016 Annual Meeting by the votes indicated below:
Name of Director Nominee |
For | Against | Abstain | Broker Non-Vote | ||||||||||||||||||||||||||||
Gerald E. Crocker |
8,994,549 | 12 | 20,000 | | ||||||||||||||||||||||||||||
Robert Bo Liess |
8,394,561 | 600,000 | 20,000 | | ||||||||||||||||||||||||||||
Wendy F. DiCicco |
8,994,561 | | 20,000 | | ||||||||||||||||||||||||||||
David Pohl |
8,994,561 | | 20,000 | | ||||||||||||||||||||||||||||
Alex Giaquinto, PhD |
8,994,561 | | 20,000 | | ||||||||||||||||||||||||||||
Elie Khalife |
8,994,561 | | 20,000 | | ||||||||||||||||||||||||||||
Steven Rule |
8,994,549 | 12 | 20,000 | |
(2) Advisory vote on executive compensation.
For
|
Against | Abstain | Broker Non-Vote | |||||||||||||
8,158,549
|
836,012 | 20,000 | |
(3) Advisory vote on the frequency of future votes on executive compensation.
One Year
|
Two Years | Three Years | Abstain | |||||||||||||||
5,995,759
|
1,380,060 | 838,742 | 800,000 |
(4) Ratification of the appointment of KLJ & Associates, LLP as the Companys independent registered public accounting firm for Fiscal Year 2015.
For
|
Against | Abstain | Broker Non-Vote | |||||||||||
8,994,561
|
- | 20,000 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CannaPharmaRx, Inc. | ||||
August 31, 2015 | By: |
/s/ Gerald E. Crocker
|
||
|
||||
Name: Gerald E. Crocker | ||||
Title: Chief Executive Officer and Director |